Table 1 Clinicopathological features and immune features of the primary tumor.
All cases | HER2 | TNBC | sTILs < 20% | sTILs≥20% | |||
|---|---|---|---|---|---|---|---|
n = 161 (%) | n = 62 (%) | n = 99 (%) | P value | n = 86 (%) | n = 75 (%) | P value | |
sTILs | |||||||
<20% | 86 (53) | 34 (55) | 52 (52) | / | / | / | |
≥20% | 75 (47) | 28 (45) | 47 (48) | 0.775a | / | / | / |
Tertiary lymphoid structures | |||||||
Absent | 123 (76) | 46 (74) | 77 (78) | 72 (84) | 51 (68) | ||
Present | 38 (24) | 16 (26) | 22 (22) | 0.602a | 14 (16) | 24 (32) | 0.019a |
Age at diagnosis | |||||||
<50 | 66 (41) | 20 (32) | 46 (46) | 35 (41) | 31 (41) | ||
≥50 | 95 (59) | 42 (68) | 53 (54) | 0.074a | 51 (59) | 44 (59) | 0.935a |
Tumor size | |||||||
pT1 | 33 (21) | 11 (18) | 22 (22) | 12 (14) | 21 (28) | ||
pT2 | 116 (72) | 46 (74) | 70 (71) | 65 (76) | 51 (68) | ||
pT3 | 10 (6) | 4 (6) | 6 (6) | 8 (9) | 2 (3) | ||
pT4 | 2 (1) | 1 (2) | 1 (1) | 0.906a | 1 (1) | 1 (1) | 0.071a |
Histological grade | |||||||
III | 161 (100) | 62 (100) | 99 (100) | 86 (100) | 75 (100) | ||
Lymphovascular invasion | |||||||
Absent | 51 (32) | 13 (21) | 38 (38) | 24 (28) | 27 (36) | ||
Present | 110 (68) | 49 (79) | 61 (62) | 0.021a | 62 (72) | 48 (64) | 0.271a |
Lymph node status | |||||||
pN1 (1–3) | 90 (56) | 27 (44) | 63 (64) | 47 (55) | 43 (57) | ||
pN2 (4–9) | 39 (24) | 18 (29) | 21 (21) | 20 (23) | 19 (25) | ||
pN3 (>=10) | 32 (20) | 17 (27) | 15 (15) | 0.037a | 19 (22) | 13 (18) | 0.748a |
Chemotherapy | |||||||
Anthracycline + taxane | 137 (85) | 55 (89) | 82 (83) | 77 (90) | 60 (80) | ||
Anthracycline | 19 (12) | 5 (8) | 14 (14) | 7 (8) | 12 (16) | ||
Taxane | 5 (3) | 2 (3) | 3 (3) | 0.508a | 2 (2) | 3 (4) | 0.236a |
Local or regional tumor recurrence | |||||||
Absent | 144 (89) | 55 (89) | 89 (90) | 73 (85) | 71 (95) | ||
Present | 17 (11) | 7 (11) | 10 (10) | 0.811a | 13 (15) | 4 (5) | 0.044a |
Distant metastasis | |||||||
Absent | 119 (74) | 46 (75) | 73 (74) | 52 (60) | 67 (89) | ||
Present | 42 (26) | 16 (25) | 26 (26) | 0.949a | 34 (40) | 8 (11) | <0.001a |
Breast cancer-specific death | |||||||
Absent | 127 (79) | 47 (76) | 80 (81) | 57 (66) | 70 (93) | ||
Present | 34 (21) | 15 (24) | 19 (20) | 0.449a | 29 (34) | 5 (7) | <0.001a |
